CAAMTECH, INC.

The disclosure relates to (2-{4-[(2,2-dimethylpropanoyl)oxy]-1H-indol-3-yl}ethyl)(methyl)azanium chloride (4-pivaloyloxy-N-methyltryptammonium chloride), crystalline 4-pivaloyloxy-N-methyltryptammonium chloride, and specific crystalline forms thereof, including crystalline form 1 of 4-pivaloyloxy-N-methyltryptammonium chloride, to compositions containing the same, and to methods of treatment using them.

Disclosed herein are compositions comprising a serotonergic tryptamine compound, combinations thereof, and methods of using them for treating and preventing a variety of human conditions. In one embodiment, disclosed herein are new compositions and methods which comprise a therapeutically effective amount of a first purified psilocybin derivative and a therapeutically effective amount of a second compound. The second compound is selected from the group consisting of a second purified psilocybin derivative, a purified terpene, a serotonergic drug, an adrenergic drug, a dopaminergic drug, a purified erinacine, and a purified hericenone.

The disclosure relates to 2-[2-ethoxy-4-(ethylsulfanyl)-5-methoxy phenyl]ethan-1-aminium chloride (2-(2-ethoxy-4-(ethylthio)-5-methoxyphenyl) ethan-1-aminium chloride), crystalline 2-(2-ethoxy-4-(ethylthio)-5-methoxyphenyl) ethan-1-aminium chloride, and specific crystalline forms thereof, including crystalline form 1 of 2-(2-ethoxy-4-(ethylthio)-5-methoxyphenyl) ethan-1-aminium chloride, to compositions containing the same, and to methods of treatment using it.

The disclosure relates to a compound of formula (I): The disclosure also relates compound of formula (Ia): The disclosure relates to compositions comprising, consisting essentially of, or consisting of a compound of formula (I) or formula (Ia) and an excipient. The disclosure also relates to pharmaceutical compositions comprising a therapeutically effective amount of a compound of formula (I) or formula (Ia) where the excipient is a pharmaceutically acceptable carrier. The disclosure further relates to therapeutic uses of compounds of formula (I) or formula (Ia).

The disclosure relates to 5-methoxy-N,N-diallyltryptamine (“5-MeO-DALT”), bis-(5-meth-oxy-N,N-di-allyl-tryptammonium) fumarate (“5-MeO-DALT fumarate”), and crystalline bis-(5-meth-oxy-N,N-di-allyl-tryptammonium) fumarate (“5-MeO-DALT fumarate”), compositions containing them, and the methods of treatment using them.

The disclosure relates to forms of 5-[(3-{2-[bis(propan-2-yl)azaniumyl]ethyl}-1H-indol-4-yl)oxy]-5-oxopentanoate, including solvates such as methanol 5-[(3-{2-[bis(propan-2-yl)azaniumyl]ethyl}-1H-indol-4-yl)oxy]-5-oxopentanoate (also referred to as 4-glutarato-N,N-diisopropyltryptamine methanol solvate or 4-glutarato-DiPT-MeOH), and crystalline forms thereof such as crystalline form 1 of 4-glutarato-DiPT-MeOH and ethanol 5-[(3-{2-[bis(propan-2-yl)azaniumyl]ethyl}-1H-indol-4-yl)oxy]-5-oxopentanoate (4-glutarato-N,N-diisopropyltryptamine ethanol solvate or 4-glutarato-N,N-DiPT-EtOH), crystalline 4-glutarato-N,N-DiPT-EtOH, and crystalline forms thereof, including crystalline form 1 of 4-glutarato-N,N-DiPT-EtOH; and to pharmaceutical compositions containing them and to methods of treatment using them. The disclosure further relates to crystalline [3-[2-(methylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate (baeocystin), such as crystalline form 1 of baeocystin, and to pharmaceutical compositions containing crystalline baeocystin, such as crystalline form 1 of baeocystin, and to methods of treatment using it.

This disclosure relates to (2-{4-[ethanesulfonyl)oxy]-1H-indol-3-yl}ethyl)dipropylazanium chloride (4-(ethylsulfonyloxy)-N,N-di-n-propyltryptammonium chloride or 4-(ethylsulfonyloxy)-DPT chloride), crystalline 4-(ethylsulfonyloxy)-DPT chloride, [2-(1H-indol-3-yl)ethyl]tripropylazanium iodide (N,N,N-tri-n-propyltryptammonium iodide or TPT iodide), crystalline TPT iodide, [2-(5-chloro-1H-indol-3-yl)ethyl]bis(propan-2-yl)azanium iodide (5-chloro-A/,A/-di-n-isopropyltryptammonium iodide or 5-CI-DiPT iodide), crystalline 5-CI-DiPT iodide, 2-(5-chloro-1H-indol-3-yl)ethan-1-aminium hydrogen oxalate (5-chlorotryptammonium hydrogenoxalate or 5-CI-T hydrogenoxalate), crystalline 5-CI-T hydrogenoxalate, bis(2-(5-chloro-1H-indol-3-yl)ethan-1-aminium) dihydrate oxalate (5-chlorotryptammonium oxalate hydrate or 5-CI-T oxalate hydrate), crystalline 5-CI-T oxalate hydrate, and specific crystalline forms thereof, including crystalline form 1 of 4-(ethylsulfonyloxy)-DPT chloride, crystalline form 1 of TPT iodide, crystalline form of 1 of 5-CI-DiPT iodide, crystalline form 1 of 5-CI-T hydrogenoxalate, and crystalline form 1 of 5-CI-T oxalate hydrate, to compositions containing the same, and to methods of treatment using the.

The disclosure relates to [2-(5-chloro-1H-indol-3-yl)ethyl](propan-2-yl)azanium iodide (5-chloro-N isopropyltryptammonium iodide or 5-Cl-NiPT iodide), crystalline 5-Cl-NiPT iodide, [2-(5-methoxy-1H-indol-3-yl)ethyl](propan-2-yl)azanium iodide (5-methoxy-N-isopropyltryptammonium iodide or 5-MeO-NiPT iodide), crystalline 5-MeO-NiPT iodide, [2-(5-methyl-1H-indol-3-yl)ethyl](propan-2-yl)azanium iodide (5-methyl-N-isopropyltryptammonium iodide or 5-Me-NiPT iodide), crystalline 5-Me-NiPT iodide, [2-(2-methyl-1H-indol-3-yl)ethyl](propan-2-yl)azanium iodide (2-methyl-N-isopropyltryptammonium iodide or 2-Me-NiPT iodide), crystalline 2-Me-NiPT iodide, [2-(7-methyl 1H-indol-3-yl)ethyl](propan-2-yl)azanium iodide (7-methyl-N-isopropyltryptammonium iodide or 7-Me-NiPT iodide), crystalline 7-Me-NiPT iodide, [2-(5-fluoro-1H-indol-3-yl)ethyl](propan-2-yl)azanium iodide (5-fluoro-N-isopropyltryptammonium iodide or 5-F-NiPT iodide), crystalline 5-F-NiPT iodide, and specific crystalline forms thereof, including crystalline form 1 of 5-Cl-NiPT iodide, crystalline form 1 of 5-MeO-NiPT iodide, crystalline form 1 of 5-Me-NiPT iodide, crystalline form 1 of 2-Me-NiPT iodide, crystalline form 1 of 7-Me-NiPT iodide, and crystalline form 1 of 5-F-NiPT iodide, to compositions containing the same, and to methods of treatment using them. This disclosure relates to monoalkylated and dialkyled tryptamine analogs, and to methods of treatment/therapeutic uses thereof. This disclosure relates to an improved method of making monoalkylated and dialkylated tryptamine analogs.

This disclosure relates to trimethyl[2-(5-methyl-1H-indol-3-yl)ethyl]azanium iodide (5-methyl-A/,A/,A/trimethyltryptammonium iodide or 5-Me-TMT iodide), crystalline 5-Me-TMT iodide, triethyl ┌2-(5-methyl-1H-indol-3-yl)ethyl┘azanium iodide (5-methyl-A/,/V,/V-triethyltryptammonium iodide or 5-Me-TET iodide), crystalline 5-Me-TET iodide, triethyl[2-(1-methyl-1H-indol-3-yl)ethyl]azanium iodide (1-methyl-/V,/V,/V-triethyltryptammonium iodide or 1-Me-TET iodide), crystalline 1-Me-TET iodide, [2-(5-methyl-1H-indol-3-yl)ethyl]tripropylazanium acetonitrile iodide (5-methyl-/V,/V,/V-tri-n-propyltryptammonium iodide acetonitrile or 5-Me-TPT iodide acetonitrile), crystalline 5-Me-TPT iodide acetonitrile, [2-(7-methyl-1H-indol-3-yl)ethyl]tripropylazanium iodide (7-methyl-A/,A/,A/-tri-n-propyltryptammonium iodide or 7-Me-TPT iodide), crystalline 7-Me-TPT iodide, and specific crystalline forms thereof, including crystalline form 1 of 5-Me-TMT iodide, crystalline form 1 of 5-Me-TET iodide, crystalline form 1 of 1-Me-TET iodide, crystalline form 1 of 5-Me-TPT iodide acetonitrile, and crystalline form 1 of 7-Me-TPT iodide, to compositions containing the same, and to methods of treatment using them.

This disclosure pertains to new compositions and methods comprising a first serotonergic drug and a second serotonergic drug. In one embodiment, the compositions disclosed herein are used for a method of regulating a neurotransmitter receptor, e.g., a serotonin receptor. In one embodiment, the compositions disclosed herein comprise purified compounds, e.g., a purified psilocybin derivative, a purified cannabinoid, a purified terpene, a purified tryptamine, purified LSD, and/or purified MDMA.